Bone cement for sustained release of substances

• US 4,900,546 A
• Filed: 07/30/1987
• Issued: 02/13/1990
• Est. Priority Date: 07/30/1987
• Status: Expired due to Term

• Current Assignee: Howmedica Osteonics Corp. (Stryker Corporation)
• Original Assignee: Pfizer Hospital Products Group, Inc. (Pfizer Inc.)
• Inventors: Posey-Dowty, Jessica D., Arroyo, Nestor, Stark, Casper F., Higham, Paul A.
• Primary Examiner(s): Schofer, Joseph L.
• Assistant Examiner(s): Pili-Curtis, Carmen
• Application Number:
  US07/079,627
• Time in Patent Office: 929 Days
• Field of Search: 424/81, 424/78, 424/423, 623/16
• US Class Current: 514/29
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 24/001 Use of materials characterised by their function or physical properties
• CPC Class Codes: A61L 24/0015 Medicaments; Biocides
• CPC Class Codes: A61L 24/06 obtained by reactions only involving carbon-to-carbon unsaturated bonds A61L24/043, A61L24/046 take precedence
• CPC Class Codes: A61L 2430/02 for reconstruction of bones; weight-bearing implants
• CPC Class Codes: C08L 33/04 Homopolymers or copolymers of esters C08L43/04 takes precedence

Abstract

A bone cement is disclosed wherein the liquid component contains a therapeutic or diagnostic substance in combination with an emulsifying agent for said substance.

Claims

1. A bone cement composition comprising the combination of components A and B wherein:

Component A comprises a powdered polymer or copolymer of an acrylic ester and, component B comprises a liquid monomer of an acrylic ester containing (a) erythromycin or pharmaceutically acceptable salts thereof, an emulsifying agent for erythromycin, or pharmaceutically acceptable salts thereof, whereby the incorporation of erythromycin, or pharmaceutically acceptable salts thereof, is substantially in component B.

2. The bone cement of claim 1 wherein component A is polymethyl methacrylate.

3. The bone cement of claim 1 wherein component A is a copolymer of methylmethacrylate and styrene.

4. The bone cement of claim 1 wherein component B is methylmethacrylate.

5. The bone cement of claim 1 wherein said emulsifying agent is sorbitan mono-oleate polyoxyethylene.

7. A liquid monomer of an acrylic ester containing (a) erythromycin, or pharmaceutically acceptable salts thereof and (b) an emulsifying agent for erythromycin, or pharmaceutically acceptable salts thereof.

6. The bone cement of claim 7 wherein said emulsifying agent is sodium dihexyl sulfosuccinate.